NEW YORK, NY / ACCESSWIRE / January 4, 2017 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA). Such investors can obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/sva.
The investigation concerns whether Sinovac and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On December 21, 2016, SeekingAlpha.com published an article revealing that according to a recent Beijing court judgment, Weidong Ying, Chairman and CEO of Sinovac, paid bribes to Yin Hongzhang, the Deputy Director General of the Center for Drug Evaluation for the China Food and Drug Administration, and his wife, in order to assist its vaccine clinical trial and approval.
If you are aware of any facts relating to this investigation, or purchased Sinovac shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/sva. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com
SOURCE: Bronstein, Gewirtz & Grossman, LLC
ReleaseID: 452094
